

A clinical trial to evaluate the effects of inhaled nitric oxide gas among COVID-19 patients with pneumonia

Submission date 09/03/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 11/03/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 11/08/2022	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

COVID-19 is a condition caused by the coronavirus (called SARS-CoV-2) that was first identified in late 2019. This virus can infect the respiratory (breathing) system. Some people do not have symptoms but can carry the virus and pass it on to others. People who have developed the condition may develop a fever and/or a continuous cough among other symptoms. This can develop into pneumonia. Pneumonia is a chest infection where the small air pockets of the lungs, called alveoli, fill with liquid and make it more difficult to breathe. In some patients, this can progress to respiratory failure and patients may need supplemental oxygen or in severe cases, ventilator support to maintain normal oxygen levels. The death rate in patients who need mechanical ventilation to maintain oxygenation is quite high, additionally, ventilator support can lead to secondary infections and expensive healthcare costs.

Effective antivirals that could combat COVID-19 are currently unavailable. Research studies have reported the antiviral and antimicrobial activity of Nitric oxide against pathogens. It can also provide better oxygenation by widening of blood vessels (vasodilation). This trial will explore the effect of inhaled nitric oxide on clinical improvement among patients diagnosed with COVID-19 pneumonia.

Who can participate?

Adult COVID-19 pneumonia patients with respiratory failure due to inability for maintaining appropriate oxygen levels in the blood.

What does the study involve?

Eligible COVID-19 patients will be recruited into the study. Participants will be allocated to one of two groups, with an equal chance of being in either group (like tossing a coin). Participants and researchers will not have a choice in the treatment given. One group will receive standard care only and the other group will receive Inhaled Nitric Oxide using a helmet or tight sealing mask, as pulses lasting for 30 minutes at 12-hour intervals, for 3 consecutive days.

Trained research staff will collect the clinical information of each patient and nasal swabs will be collected on days 3, 5, 7, 10, and 14 post-treatment to estimate the quantity of virus (viral load).

What are the possible benefits and risks of participating?

At the time of writing, there are no proven therapies for this viral disease and if the study drug is effective it could potentially shorten the course and/or severity of the disease in patients. There are no known risks due to study participation.

Where is the study run from?

Amrita Institute of Medical Sciences (India)

When is the study starting and how long is it expected to run for?

From June 2020 to February 2021

Who is funding the study?

Amrita School of Biotechnology (India)

Who is the main contact?

Dr Aveek Jayant, jayant.aveek@gmail.com

Contact information

Type(s)

Public

Contact name

Dr Aveek Jayant

ORCID ID

<http://orcid.org/0000-0002-3465-1229>

Contact details

Department of Cardiac Anaesthesia

Amrita Institute of Medical Sciences

AIMS P.O

Kerala

Kochi

India

682041

+91-484-2851234

jayant.aveek@gmail.com

Type(s)

Scientific

Contact name

Dr Merlin Moni

Contact details

Department of General Medicine and Division of Infectious Diseases

Amrita Institute of Medical Sciences

AIMS P.O
Kerala
Kochi
India
682041
+91-484-2852250
drmerlin.blessan@gmail.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

A phase II open-label, randomized, controlled feasibility trial to compare the antiviral activity and clinical efficacy of inhaled nitric oxide gas among COVID-19 patients diagnosed with pneumonia with hypoxic respiratory failure

Study objectives

Nitric oxide increases antiviral activity and reduces hypoxic damage by improved oxygenation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 08/05/2020, Institutional Ethics Committee Amrita Institute of Medical Sciences (AIMS, Ponekkara, Kochi, Edappally, Ernakulam, Kerala 682041, India; +91 (0)484 2858750; <https://www.amritahospitals.org/>), ref: IEC/AIMS-2020/CARDANES-044

Study design

Prospective phase II open-label randomized controlled feasibility trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Prevention

Participant information sheet

See additional files

Health condition(s) or problem(s) studied

Adult COVID-19 pneumonia patients with hypoxic respiratory failure

Interventions

Eligible patients will be randomized into two arms either receiving standard of care only (control arm), or standard of care and inhaled Nitric Oxide (iNO) using a helmet or tight sealing oronasal mask (case arm). iNO will be delivered as pulses lasting for 30 min at 12 h intervals, for 3 consecutive days. iNO will be administered at the minimum FiO₂ to maintain saturations above 92%, using a V60 bilevel positive airway pressure (BiPAP) machine. The flow rates will be titrated to administer escalating doses of iNO starting from 10 ppm to 80 ppm over a period of 30 min. Following this iNO will be weaned off at the rate of 10 ppm per min.

Study patients will be started on oral Sildenafil 10 mg TID for 5 days, to prevent rebound rise in pulmonary pressures after iNO discontinuation, provided their MAP is >60 mmHg. Standard of care therapies including antivirals, steroids, anticoagulants, and other medications will be administered in both study arms as per institutional protocol.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Nitric Oxide gas

Primary outcome measure

Viral load as defined by cycle threshold measured using Real-Time Polymerase Chain Reaction Surrogate CT ratio from nasopharyngeal swab collected at baseline 3, 5, 7, 10, and 14 days

Secondary outcome measures

1. Duration of non-invasive ventilation (NIV) measured from the nursing chart and medical record evaluation recorded at 8 am and 8 pm daily by investigators during the study period collected at end of NIV
2. Duration of oxygen therapy measured from the nursing chart and medical record evaluation recorded at 8 am and 8 pm daily by investigators during the study period collected at end of oxygen therapy
3. Methaemoglobin levels measured using arterial blood gas analysis using a co- oximeter RADIOMETER ABL 800 on blood gas samples drawn after each pulse of iNO therapy at baseline, 1, 2, and 3 days
4. Incidence of methaemoglobin levels >3% during the trial measured using arterial blood gas analysis using a co- oximeter RADIOMETER ABL 800 on blood gas samples drawn after each pulse of iNO therapy at baseline, 1, 2, and 3 days
5. Severe acute respiratory infection (SARI) scale performance assessed during daily rounds by

the clinical team collected daily until ICU discharge or achievement of the lowest numeric, whichever is earlier

6. Patient status measured using the Sequential Organ Failure Assessment (SOFA) score from medical chart/investigations obtained at 8 am at baseline and 72 h

7. Length of hospital stay measured from medical chart review on the day of hospital discharge

8. Length of intensive care unit (ICU) stay measured from medical chart review on the day of ICU discharge

9. Deaths measured by investigators for all patients in each arm and followed up daily recorded on the day of death or the immediate day after

Overall study start date

10/06/2020

Completion date

05/02/2021

Eligibility

Key inclusion criteria

1. Severe acute respiratory infection (SARI) class 4 and 5 (hospitalized with the requirement of oxygen supplementation, high flow oxygen device, or non-invasive ventilation assistance)
2. Respiratory rates <30 and saturating >90% with oxygen or Non-Invasive Ventilation (NIV)

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

25

Total final enrolment

29

Key exclusion criteria

1. Mental obtundation at ICU admission
2. Contraindications or unwillingness to NIV
3. Requiring mechanical ventilation at ICU admission
4. Pre-enrollment diagnosis of chronic renal failure (CRF) or stage 1 Acute Kidney Injury (AKI) as per Kidney Disease Improving Global Outcomes (KDIGO) guidelines
5. Presence of hemoglobinopathies
6. Shock at presentation (mean arterial pressure <60)
7. History of G6PD deficiency or baseline methemoglobin >3%
8. Presence of baseline pulmonary artery hypertension
9. Pregnancy or breastfeeding

Date of first enrolment

20/09/2020

Date of final enrolment

12/12/2020

Locations

Countries of recruitment

India

Study participating centre

Amrita Institute of Medical Sciences

AIMS P.O

Ponekkara

Kochi

India

682041

Sponsor information

Organisation

Amrita Institute of Medical Sciences and Research Centre

Sponsor details

AIMS P.O

Ponekkara

Kochi

India

682041

+91 484 285 1234

md@aims.amrita.edu

Sponsor type

Hospital/treatment centre

Website

<http://www.amritahospitals.org/>

ROR

<https://ror.org/05ahcwz21>

Funder(s)

Funder type

University/education

Funder Name

Amrita School of Biotechnology

Results and Publications

Publication and dissemination plan

Planned for publication in a high-impact peer-reviewed journal. The full trial record (methods statistical plan and results) will be uploaded post-completion either as part of the trial record or on a registry of peer prints such as medrxiv.org.

Intention to publish date

05/02/2022

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		31/03/2022	11/08/2022	Yes	No